Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Huangkui Granules is a Traditional Chinese Medicine (TCM) formulation developed by the Shandong Institute of Biological Medicine for the treatment of chronic non-bacterial prostatitis (CNP). The primary active component is derived from *Abelmoschus manihot* (L.) Medic, which contains a variety of flavonoids such as myricetin, quercetin, and hyperoside. The drug exerts its therapeutic effects through multi-target anti-inflammatory and analgesic mechanisms, specifically by inhibiting the production of pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6, and by suppressing the expression of COX-2. These actions help to alleviate pelvic pain and urinary symptoms associated with chronic prostatic inflammation. It is typically administered orally in a granule dosage form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Huangkui Granules.